ocaperidone has been researched along with Migraine Disorders in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gommeren, W; Haegeman, G; Heylen, L; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van de Weyer, I; Van Gompel, P; Vanhoenacker, P; Wouters, R | 1 |
1 other study(ies) available for ocaperidone and Migraine Disorders
Article | Year |
---|---|
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
Topics: Animals; Benzopyrans; Cattle; Cloning, Molecular; Glioma; HeLa Cells; Humans; Mice; Migraine Disorders; Propylamines; Protein Binding; Pyrimidines; Radioligand Assay; Receptors, Serotonin; Serotonin Receptor Agonists; Signal Transduction; Tritium; Tumor Cells, Cultured; Vasoconstrictor Agents | 1996 |